LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $64.25.
A number of research analysts have recently weighed in on LMAT shares. Roth Capital raised their price target on shares of LeMaitre Vascular from $55.00 to $58.00 and gave the company a “neutral” rating in a report on Tuesday, August 3rd. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 3rd. Barrington Research lifted their target price on shares of LeMaitre Vascular from $59.00 to $64.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Finally, Jefferies Financial Group initiated coverage on shares of LeMaitre Vascular in a report on Thursday, September 16th. They issued a “buy” rating and a $70.00 target price on the stock.
Several large investors have recently bought and sold shares of LMAT. Advisory Services Network LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $74,000. Lazard Asset Management LLC increased its holdings in shares of LeMaitre Vascular by 38.8% during the 1st quarter. Lazard Asset Management LLC now owns 1,641 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 459 shares during the period. Altshuler Shaham Ltd increased its holdings in shares of LeMaitre Vascular by 113.1% during the 1st quarter. Altshuler Shaham Ltd now owns 2,116 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 1,123 shares during the period. Mutual of America Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 7.8% during the 2nd quarter. Mutual of America Capital Management LLC now owns 2,432 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 177 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $177,000. Institutional investors own 80.63% of the company’s stock.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, July 29th. The medical instruments supplier reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $40.67 million for the quarter, compared to the consensus estimate of $40.70 million. LeMaitre Vascular had a net margin of 19.12% and a return on equity of 16.51%. As a group, equities research analysts predict that LeMaitre Vascular will post 1.37 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 9th. Investors of record on Thursday, August 26th were issued a $0.11 dividend. The ex-dividend date was Wednesday, August 25th. This represents a $0.44 annualized dividend and a yield of 0.79%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.31%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.
Featured Story: Stocks Increasing Dividends
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.